papillary thyroid carcinoma
*based on 3 hot thyroid carcinoma investigated by Mircescu et al. 2000, Lado-Abeal et al. 2010, Xu et al. 2019
Lado-Abeal: co-occuring with Pax8PPAR?
Xu: Also had the following copy number alterations: Gain of 5, 10, 12, 17, 18, 20, 21, X; WCD of 7; Copy neutral LOH in 9
Lado-Abeal: total thyroidectomy, 2 years L-T4 suppressive
cAMP (basal): basal in vitro cAMP production of mutant over wild-type TSHR
cAMP (TSH): maximal in vitro cAMP production of mutant over wild-type TSHR
IP (basal): basal in vitro IP production of mutant over wild-type TSHR
IP (TSH): maximal in vitro IP production of mutant over wild-type TSHR
TSH-binding: maximal TSH-binding compared to the wild-type TSHR
Cell surface expression: cell surface expression of mutant compared to WT-TSHR
LRA: linear regression analysis (LRA) of constitutive activity as a function of TSHR expression determined by 125I-bTSH binding or FACS analysis compared to the wild-type TSHR
Prevalence: Prevalence of (somatic and germline) activating mutations*
Ref: Reference for functional characterization
Child: Found in children.